300 related articles for article (PubMed ID: 34386358)
1. Current advances of targeting epigenetic modifications in neuroendocrine prostate cancer.
Cheng WC; Wang HJ
Tzu Chi Med J; 2021; 33(3):224-232. PubMed ID: 34386358
[TBL] [Abstract][Full Text] [Related]
2. The epigenetic and transcriptional landscape of neuroendocrine prostate cancer.
Davies A; Zoubeidi A; Selth LA
Endocr Relat Cancer; 2020 Feb; 27(2):R35-R50. PubMed ID: 31804971
[TBL] [Abstract][Full Text] [Related]
3. The Role of Epigenetic Change in Therapy-Induced Neuroendocrine Prostate Cancer Lineage Plasticity.
Storck WK; May AM; Westbrook TC; Duan Z; Morrissey C; Yates JA; Alumkal JJ
Front Endocrinol (Lausanne); 2022; 13():926585. PubMed ID: 35909568
[TBL] [Abstract][Full Text] [Related]
4. Molecular model for neuroendocrine prostate cancer progression.
Chen R; Dong X; Gleave M
BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310
[TBL] [Abstract][Full Text] [Related]
5. Lineage plasticity and treatment resistance in prostate cancer: the intersection of genetics, epigenetics, and evolution.
Imamura J; Ganguly S; Muskara A; Liao RS; Nguyen JK; Weight C; Wee CE; Gupta S; Mian OY
Front Endocrinol (Lausanne); 2023; 14():1191311. PubMed ID: 37455903
[TBL] [Abstract][Full Text] [Related]
6. Treatment-induced neuroendocrine prostate cancer and
Wishahi M
World J Clin Cases; 2024 May; 12(13):2143-2146. PubMed ID: 38808339
[TBL] [Abstract][Full Text] [Related]
7. Role of transcription factors and chromatin modifiers in driving lineage reprogramming in treatment-induced neuroendocrine prostate cancer.
Sreekumar A; Saini S
Front Cell Dev Biol; 2023; 11():1075707. PubMed ID: 36711033
[TBL] [Abstract][Full Text] [Related]
8. Reprogramming hormone-sensitive prostate cancer to a lethal neuroendocrine cancer lineage by mitochondrial pyruvate carrier (MPC).
Xu H; Liu Z; Gao D; Li P; Shen Y; Sun Y; Xu L; Song N; Wang Y; Zhan M; Gao X; Wang Z
Mol Metab; 2022 May; 59():101466. PubMed ID: 35219875
[TBL] [Abstract][Full Text] [Related]
9. TRIM59 is suppressed by androgen receptor and acts to promote lineage plasticity and treatment-induced neuroendocrine differentiation in prostate cancer.
Fan L; Gong Y; He Y; Gao WQ; Dong X; Dong B; Zhu HH; Xue W
Oncogene; 2023 Feb; 42(8):559-571. PubMed ID: 36544044
[TBL] [Abstract][Full Text] [Related]
10. Clinical and Biological Features of Neuroendocrine Prostate Cancer.
Yamada Y; Beltran H
Curr Oncol Rep; 2021 Jan; 23(2):15. PubMed ID: 33433737
[TBL] [Abstract][Full Text] [Related]
11. The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.
Bishop JL; Thaper D; Vahid S; Davies A; Ketola K; Kuruma H; Jama R; Nip KM; Angeles A; Johnson F; Wyatt AW; Fazli L; Gleave ME; Lin D; Rubin MA; Collins CC; Wang Y; Beltran H; Zoubeidi A
Cancer Discov; 2017 Jan; 7(1):54-71. PubMed ID: 27784708
[TBL] [Abstract][Full Text] [Related]
12. MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer.
Yasumizu Y; Rajabi H; Jin C; Hata T; Pitroda S; Long MD; Hagiwara M; Li W; Hu Q; Liu S; Yamashita N; Fushimi A; Kui L; Samur M; Yamamoto M; Zhang Y; Zhang N; Hong D; Maeda T; Kosaka T; Wong KK; Oya M; Kufe D
Nat Commun; 2020 Jan; 11(1):338. PubMed ID: 31953400
[TBL] [Abstract][Full Text] [Related]
13. Cellular plasticity and the neuroendocrine phenotype in prostate cancer.
Davies AH; Beltran H; Zoubeidi A
Nat Rev Urol; 2018 May; 15(5):271-286. PubMed ID: 29460922
[TBL] [Abstract][Full Text] [Related]
14. Role of MicroRNAs in Neuroendocrine Prostate Cancer.
Sreekumar A; Saini S
Noncoding RNA; 2022 Mar; 8(2):. PubMed ID: 35447888
[TBL] [Abstract][Full Text] [Related]
15. Dynamics of Cellular Plasticity in Prostate Cancer Progression.
Tiwari R; Manzar N; Ateeq B
Front Mol Biosci; 2020; 7():130. PubMed ID: 32754615
[TBL] [Abstract][Full Text] [Related]
16. Increased Serine and One-Carbon Pathway Metabolism by PKCλ/ι Deficiency Promotes Neuroendocrine Prostate Cancer.
Reina-Campos M; Linares JF; Duran A; Cordes T; L'Hermitte A; Badur MG; Bhangoo MS; Thorson PK; Richards A; Rooslid T; Garcia-Olmo DC; Nam-Cha SY; Salinas-Sanchez AS; Eng K; Beltran H; Scott DA; Metallo CM; Moscat J; Diaz-Meco MT
Cancer Cell; 2019 Mar; 35(3):385-400.e9. PubMed ID: 30827887
[TBL] [Abstract][Full Text] [Related]
17. ID2 Promotes Lineage Transition of Prostate Cancer through FGFR and JAK-STAT Signaling.
Zhang J; Chen Z; Mao Y; He Y; Wu X; Wu J; Sheng L
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254880
[TBL] [Abstract][Full Text] [Related]
18. Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas.
Kleb B; Estécio MR; Zhang J; Tzelepi V; Chung W; Jelinek J; Navone NM; Tahir S; Marquez VE; Issa JP; Maity S; Aparicio A
Epigenetics; 2016 Mar; 11(3):184-93. PubMed ID: 26890396
[TBL] [Abstract][Full Text] [Related]
19. Development of Neuroendocrine Prostate Cancers by the Ser/Arg Repetitive Matrix 4-Mediated RNA Splicing Network.
Lee AR; Che N; Lovnicki JM; Dong X
Front Oncol; 2018; 8():93. PubMed ID: 29666783
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic (De)regulation in Prostate Cancer.
Xu C; Zhao S; Cai L
Cancer Treat Res; 2023; 190():321-360. PubMed ID: 38113006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
